annamycin

Annamycin is a next-generation anthracycline antibiotic and potent topoisomerase II inhibitor being developed primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma. Unlike traditional anthracyclines such as doxorubicin, annamycin is formulated to avoid dose-limiting cardiotoxicity, allowing for higher cumulative dosing without the risk of heart damage. Its mechanism involves intercalation into DNA and inhibition of topoisomerase II by stabilizing the DNA-topoisomerase II complex, leading to double-strand DNA breaks and cell death. Annamycin has demonstrated strong efficacy in drug-resistant cancer cell lines and shows synergistic activity with various FDA-approved anticancer agents across both hematologic malignancies (like AML) and solid tumors (such as sarcomas and pancreatic cancer). The drug is being evaluated in pivotal clinical trials including combination regimens with cytarabine for AML[1][2][3][5][6].

Other names

liposomal annamycinL-annamycin